R
Rob Pieters
Researcher at Boston Children's Hospital
Publications - 668
Citations - 33429
Rob Pieters is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Leukemia & Acute lymphocytic leukemia. The author has an hindex of 95, co-authored 638 publications receiving 29894 citations. Previous affiliations of Rob Pieters include VU University Amsterdam & Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
Monique L. den Boer,Marjon van Slegtenhorst,Renee X. de Menezes,Renee X. de Menezes,Meyling Cheok,Jessica Buijs-Gladdines,Susan T C J M Peters,Laura J. C. M. van Zutven,H. Berna Beverloo,Peter J. van der Spek,Gaby Escherich,Martin A. Horstmann,Gritta Janka-Schaub,Willem A. Kamps,William E. Evans,Rob Pieters +15 more
TL;DR: A genome-wide study to improve prognostic classification of ALL in children revealed a new ALL subtype, the underlying genetic abnormalities of which were characterised by comparative genomic hybridisation-arrays and molecular cytogenetics.
Journal ArticleDOI
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Ching-Hon Pui,Jun J. Yang,Stephen P. Hunger,Rob Pieters,Martin Schrappe,Andrea Biondi,Ajay Vora,André Baruchel,Lewis B. Silverman,Kjeld Schmiegelow,Gabriele Escherich,Keizo Horibe,Yves Benoit,Shai Izraeli,Allen Eng Juh Yeoh,Der Cherng Liang,James R. Downing,William E. Evans,Mary V. Relling,Charles G. Mullighan +19 more
TL;DR: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.
Journal ArticleDOI
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors
Jennifer O'Neil,Jonathan E. Grim,Peter Strack,Sudhir Rao,Deanne Tibbitts,Christopher Winter,James S. Hardwick,Markus Welcker,Jules P.P. Meijerink,Rob Pieters,Giulio Draetta,Rosalie C. Sears,Bruce E. Clurman,A. Thomas Look +13 more
TL;DR: It is shown that all seven leukemic cell lines with FBW7 mutations were resistant to the MRK-003 GSI and most of these resistant lines also failed to down-regulate the mRNA levels of the NOTCH targets MYC and DELTEX1 after treatment with MRk-003, implying that residual NOTCH signaling in T-ALLs with FBw7 mutations contributes to GSI resistance.
Journal ArticleDOI
Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment
Amy Holleman,Meyling Cheok,Monique L. den Boer,Wenjian Yang,Anjo J.P. Veerman,Karin M. Kazemier,Deqing Pei,Cheng Cheng,Ching-Hon Pui,Mary V. Relling,Gritta Janka-Schaub,Rob Pieters,William E. Evans +12 more
TL;DR: Differential expression of a relatively small number of genes is associated with drug resistance and treatment outcome in childhood ALL.
Journal ArticleDOI
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.
Rob Pieters,Martin Schrappe,Paola De Lorenzo,Ian Hann,Giulio Rossi,Maria S. Felice,Liisa Hovi,Thierry Leblanc,Tomasz Szczepański,Alina Ferster,Gritta Janka,Jeffrey E. Rubnitz,Lewis B. Silverman,Jan Stary,Myriam Campbell,Chi Kong Li,Georg Mann,Ram Suppiah,Andrea Biondi,Ajay Vora,Maria Grazia Valsecchi +20 more
TL;DR: Patients treated with the hybrid protocol, and especially those who responded poorly to prednisone, had higher EFS than most reported outcomes for treatment of infant ALL, and Delayed intensification of chemotherapy did not benefit patients.